In 1998, the same year “Footloose” debuted on Broadway, REMICADE® (infliximab) was approved by the FDA for the treatment of Crohn’s disease. This was the first monoclonal antibody ever used to treat a chronic condition, and it upended the treatment of Crohn’s disease. Infliximab and ENBREL® (etanercept) — also approved in 1998 and used to treat rheumatoid arthritis — were the first FDA-approved tumor necrosis factor-α (TNF) inhibitors. TNF is part of a large family of signaling proteins known to play a key role in developing and coordinating the immune system. The early success of infliximab and etanercept generated excitement among researchers and within the pharmaceutical industry at the possibility of targeting other members of this protein family. As “Footloose” made it back to Broadway in 2024 for the first time since its initial run, therapies targeting the TNF family are in the midst of their own revival. Carl Ware, PhD, a professor in the Immunity and Pathogenesis Program at Sanford Burnham Prebys, and collaborators at the La Jolla Institute for Immunology and biotechnology company Inhibrx, report in Nature Reviews Drug Discovery that there is a resurgence of interest and investment in these potential treatments. Read more: https://lnkd.in/gX-Q5UMb.
Sanford Burnham Prebys
Research Services
La Jolla, CA 15,381 followers
We conduct world-class, collaborative, biological research and translate discoveries for the benefit of patients.
About us
Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding basic human biology and disease and advancing scientific discoveries to profoundly impact human health. Our track record of pioneering research spans more than 40 years and has produced breakthroughs in cancer, neuroscience, immunology and children’s diseases and is anchored by our NCI-designated Cancer Center. Sanford Burnham Prebys’ drug discovery center and global partnerships propel our prototype drugs and therapeutic strategies toward improving human health. A deep culture of collaboration and commitment to educating the next generation of scientists unites Sanford Burnham Prebys researchers, partners and philanthropists in a shared mission to improve human health.
- Website
-
http://www.sbpdiscovery.org
External link for Sanford Burnham Prebys
- Industry
- Research Services
- Company size
- 501-1,000 employees
- Headquarters
- La Jolla, CA
- Type
- Nonprofit
- Founded
- 1976
- Specialties
- stem cells, drug discovery, cancer research, diabetes research, rare and neglected diseases, neurodegenerative diseases, metabolism and obesity, children's diseases, core technology services, infectious and inflammatory diseases, aging research, pediatric cancer research, Crohn's disease, autism, inflammatory bowel disease, brain injuries, Alzheimer's disease, Parkinson's disease, cardiovascular disease, and calcification
Locations
-
Primary
10901 North Torrey Pines Rd.
La Jolla, CA 92037, US
-
6400 Sanger Rd.
Orlando, FL 32827, US
Employees at Sanford Burnham Prebys
-
Janelle Nelson
Sr. Major Gifts Officer at Sanford Burnham Preybs Medical Discovery Institute
-
Piotr Cieplak
Research Associate Professor at SBP Medical Discovery Institute
-
Maximiliano D'Angelo
Associate Professor & Associate Director at Sanford Burnham Prebys NCI-Designated Cancer Center
Updates
-
For one San Diegan scientist at Sanford Burnham Prebys, the March 2024 federal approval of a new drug to treat Duchenne muscular dystrophy (DMD) marked a milestone in three decades of studying muscle regeneration and muscle-wasting diseases. The compound, called Givinostat and marketed as DUVYZAT™, is a histone deacetylase inhibitor and was approved by the FDA for the treatment of boys with DMD. “I have been working from the very beginning of my research career to translate early, basic discoveries into a treatment for DMD,” said Pier Lorenzo Puri, MD, director and professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys. Read more: https://lnkd.in/gtRWM3uG.
-
Sanford Burnham Prebys physician-scientist Evan Snyder, MD, PhD, was reappointed to the Cellular, Tissue, and Gene Therapies Advisory Committee in the Center for Biologics Evaluation and Research at the Food and Drug Administration. He will serve a four-year term from August 30, 2024, to March 31, 2028. We sat down with Snyder to learn more about the committee, his advisory role and the importance of safeguards for new therapies. Read more: https://lnkd.in/gaJF3r3q.
-
On Wednesday, November 6, 2024, Chairmen’s Hall on the Sanford Burnham Prebys campus was transformed by the sights, smells and sounds of Día de los Muertos. Día de los Muertos is held on November 1 and 2 each year. It provides an opportunity for families and communities to ceremonially welcome back the souls of deceased loved ones for a reunion. Central to the holiday are altars called ofrendas, or “offerings,” that include personal mementos and symbolic items meant to help guide back the souls of family members. Some symbols also highlight the celebration’s focus on enjoying the sweetness of life even while recognizing the inevitability of death. The Día de los Muertos event at Sanford Burnham Prebys featured an ofrenda that was constructed through community participation. In the weeks prior, attendees were able to attend two arts and crafts sessions to make wooden sugar skulls and decorate picture frames for the ofrenda. Read more: https://bit.ly/3NWV79s #DíadelosMuertos
-
The Sanford Burnham Prebys Wellness Ambassadors hosted a Science Connect event on Wednesday, October 30, 2024, featuring two faculty experts discussing their breast cancer research and its implications. The Science Connect Series provides a forum for Sanford Burnham Prebys principal investigators to share their research with administrative personnel. The immune system is one of the main defenses of the human body to fend off harmful pathogens and invasive cells, such as cancer. Kelly Kersten, PhD, wants to understand why immune cells called T cells enter a state known as exhaustion and lose their tumor-killing capacity. This knowledge will help her team find potential future therapies that could prevent T-cell exhaustion and improve immunotherapies for cancer patients. Kevin Tharp, Ph.D., presented his team’s work with the Kersten lab on another aspect of potential resistance to immunotherapy in breast cancer. Tharp and Kersten are studying the hypothesis that part of the reason why these therapies fail is due to tumor-associated fibrosis, the creation of a thick layer of fibrous collagen (like scar tissue) that acts as a barrier against the anti-tumor immune response. Read more: https://bit.ly/40MEapZ #breastcancer #breastcancerresearch #tcellexhaustion #immunotherapy #sandiego #lajolla #torreypines
-
David Brenner, MD, president and CEO of Sanford Burnham Prebys, welcomed attendees to the launch of a new community engagement program called “A Conversation About” in the institute’s Victor E. LaFave III Memorial Auditorium on October 9, 2024. The initial panel discussion in the A Conversation About series focused on the connection between aging and cancer and included information about a current breast cancer research collaboration. Watch the full recording here: https://bit.ly/4eY2ucm #aging #cancer #biomedicalresearch #sandiego #lajolla #torreypines
-
Don't miss out on an enlightening session with Dr. Jason Cantor, assistant professor in the Department of Biochemistry at the University of Wisconsin-Madison, as he explores the fascinating interplay of genetic and environmental factors in human cell fitness. Join us for Focus On: Cancer Metabolism on Monday, October 28th, from 12:00-1:00 PM PT. This event is hosted by Kevin Tharp, Ph.D. and organized by the NCI-Designated Cancer Center at Sanford Burnham Prebys. Register today: https://bit.ly/3Uk2Qlz #cancer #cancerresearch #cancermetabolism #biology #biochemistry #sandiego #lajolla #torreypines
-
Alicia Llorente Lope, PhD, and Ambroise Manceau, PhD, were awarded 2024 Postdoctoral Fellowships from the American Cancer Society. These prestigious awards provide more than $65,000 per year for up to three years to support early career scientists studying cancer. “I was so excited when I heard the news,” said Llorente. “It is a privilege to have this award, and it feels very validating to know that someone saw enough potential in my research to deem it worthy of funding.” Llorente’s fellowship project will tackle treatment resistance in a subtype of breast cancer, while Manceau will focus on powering down pancreatic cancer cells by starving them. Read more: https://bit.ly/40bvetU #postdoctoralfellowship #cancerresearch #biomedicalresearch #breastcancer #pancreaticcancer #sandiego #lajolla #torreypines
-
Sanford Burnham Prebys reposted this
📌 Sanford Burnham Prebys will be at the SACNAS NDiSTEM Conference in Phoenix, Arizona from October 31st - November 2nd! Come meet Lauren Mitchell and Sara Sandoval at booth #215 in the exhibit hall to learn more about our research institute's opportunities and how you can get a PhD in Biomedical Sciences at our Graduate School. #SanfordBurnhamPrebys #SACNAS #2024NDiSTEM #TrueDiversity #STEM #BiomedicalScience #ResearchCareers
-
Scientists have linked neuropsychiatric disorders, such as schizophrenia and autism, to changes in many genes involved in early brain development. However, more research is needed to understand how these gene variants influence the biological mechanisms that underlie these disorders. Anne Bang, PhD, director of Cell Biology at the Conrad Prebys Center for Chemical Genomics, is part of an interdisciplinary team of scientists and clinicians working to establish clearer connections between the implicated genes and their effects on brain function and mental health. Under the leadership of Jonathan Sebat, PhD, a professor in the departments of Psychiatry and Cellular & Molecular Medicine at UC San Diego School of Medicine, the group was awarded a $12.7 million grant from the California Institute for Regenerative Medicine (CIRM) to create a new research center to support this work. https://bit.ly/3BE0veP #neuropsychiatricdisorders #schizophrenia #autism #cellbiology #chemicalgenomics #mentalhealth